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Abstract
Hereditary, hormonal, and behavioral factors contribute to the development of breast can-
cer. Alcohol consumption is a modifiable behavior that is linked to increased breast cancer
risks and is associated with the development of hormone-dependent breast cancers as well
as disease progression and recurrence following endocrine treatment. In this study we
examined the molecular mechanisms of action of alcohol by applying molecular, genetic,
and genomic approaches in characterizing its effects on estrogen receptor (ER)-positive
breast cancer cells. Treatments with alcohol promoted cell proliferation, increased growth
factor signaling, and up-regulated the transcription of the ER target gene GREB1 but not the
canonical target TFF1/pS2. Microarray analysis following alcohol treatment identified a
large number of alcohol-responsive genes, including those which function in apoptotic and
cell proliferation pathways. Furthermore, expression profiles of the responsive gene sets in
tumors were strongly associated with clinical outcomes in patients who received endocrine
therapy. Correspondingly, alcohol treatment attenuated the anti-proliferative effects of the
endocrine therapeutic drug tamoxifen in ER-positive breast cancer cells. To determine the
contribution and functions of responsive genes, their differential expression in tumors were
assessed between outcome groups. The proto-oncogene BRAF was identified as a novel
alcohol- and estrogen-induced gene that showed higher expression in patients with poor
outcomes. Knock-down of BRAF, moreover, prevented the proliferation of breast cancer
cells. These findings not only highlight the mechanistic basis of the effects of alcohol on
breast cancer cells and increased risks for disease incidents and recurrence, but may facili-
tate the discovery and characterization of novel oncogenic pathways and markers in breast
cancer research and therapeutics.
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Introduction
This year, more than 230,000 women in the US will develop breast cancer, currently one of the
most common causes of cancer deaths in American women (Cancer Facts and Figures, American
Cancer Society, 2014). A better understanding of risk factors involved in the development of
breast cancer may provide more effective preventative measures as well as more targeted thera-
peutics. Many environmental factors are known to increase breast cancer risk, including modifi-
able behaviors such as alcohol consumption. Epidemiological studies have strongly linked
alcohol consumption to increased breast cancer risk [1–4]. Moreover, these studies also show
that breast cancer risk is positively correlated with the amount of alcohol consumed. Alcohol
consumption also positively correlates with increases in breast area covered by dense parenchy-
mal tissue and decreased β-carotene circulation, parameters which are individually known to
result in increased breast cancer risk [5–8]. Furthermore, some gene product mutations (such as
GSTM1) potentiate the risk for alcohol-associated cancers [9]. Given the popularity of alcohol
consumption among women in the United States and a significant number of those with alcohol
use disorder, alcohol consumption is a key modifiable factor in the development of breast cancer.
Alcohol-associated breast cancers tend to be estrogen receptor (ER)-positive and progesterone
receptor (PR)-positive [5, 10–13]. Studies examining the potential effects of alcohol consumption
on the amount of circulating estrogens in the body have failed to identify a consistent correlation,
suggesting that alcohol likely mediates more direct effects on signaling mechanisms in the breast
to promote carcinogenesis [14, 15]. It has been shown that alcohol stimulates proliferation, up-reg-
ulates ERα and aromatase expression, and attenuates BRCA1 expression in ER+ cell lines [16, 17].
Furthermore, it has been previously shown that alcohol up-regulates polymerase III specific genes,
and that this effect is countered by treatment with ER antagonists [18, 19]. Alcohol has also been
shown to increase the migration and invasion of breast cancer cell lines, which could be mediated
through decreased E-cadherin expression, or up-regulated matrix metalloproteinase secretion [20,
21]. Conversely, alcohol has been shown to suppress lung metastasis of 4T1.2 breast cancer cells,
which are ER- [22]. These results are difficult to interpret due to the tendency of alcohol-associated
cancers to be ER+/PR+. However, another study shows that alcohol increases lung metastasis of
the ER+MADB106 breast cancer cells [23]. These experiments were performed in male rats, but
suggest that alcohol may regulate breast carcinogenesis in an estrogen-dependent manner. ER and
PR are markers of estrogen-dependent tumor growth and sensitivity to endocrine therapy with
selective estrogen receptor modulators (SERMs) or aromatase inhibitors which block estrogen
production [24]. Patients, especially postmenopausal women, who consumed alcohol while receiv-
ing endocrine therapy had a higher risk of recurrence [25]. In context of the epidemiology, It is
estimated that 50% of women with breast cancer drink at least some alcohol (> 0.5 g/day), which
represents a very large population and suggests a potential interaction between endocrine therapy
and alcohol in vivo [25]. The full extent of the impact of alcohol on ER-regulated and ER-indepen-
dent mechanisms remains to be determined, including interactions between alcohol, estrogen, and
SERMs used to treat hormone-dependent breast cancers. In this study, we investigated the effects
of alcohol on growth factor and estrogen signaling, gene regulatory networks involved in clinical
outcomes in breast cancer patients, the effects of alcohol on tamoxifen response in ER+ cell lines,
as well as the functions of alcohol-regulated genes in breast cancer cell proliferation.
Materials and Methods
Cell Culture
Three standard human breast cancer cell lines were selected for use in these studies: MCF-7,
T47D, and MDA-MB-231, (American Type Culture Collection, Rockville, MD, USA). MCF-7
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cells were grown in high glucose Dulbecco’s modified Eagle’s medium buffered in HEPES
(Invitrogen, Carlsbad, CA, USA). The media were supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT, USA). T47D and MDA-MB-231 cells were grown in DMEM/F12 (Invi-
trogen) containing HEPES and glutamine. These cells were further supplemented with 10%
FBS (Hyclone). Cells requiring estrogen-depletion were washed in PBS and grown in DMEM
or DMEM/F12 lacking phenol and supplemented with 10% charcoal/dextran filtered fetal
bovine serum (Hyclone).
Cell Proliferation Assays, Cell Treatments, and Gene Knockdowns
Cells were treated with 10 nm 17β-estradiol (Sigma-Aldrich, St. Louis, MO, USA), 500 nm
4-hydroxytamoxifen (Tocris Bioscience, Bristol, UK), ethanol, or with DMSO as a vehicle. Cell
proliferation was measured in one of two ways. Trypan blue exclusion assays were used to
manually count cells using a hemocytometer. Otherwise, cell proliferation was measured using
a standard MTS reagent, CellTiter96 Aqueous One Solution (Promega, Madison, WI, USA),
according to the manufacture’s standard protocol. For combination treatment experiments,
7500 MCF-7 or T47D cells were seeded in a 96-well format, whereas 5000 MDA-MB-231 cells
were similarly seeded for experimentation. Statistical analysis of these experiments was carried
out using a standard two-tailed Student’s t-test. All experiments were performed in triplicate.
BRAF knockdown was accomplished by transfecting breast cancer cell lines with one of two
targeting siRNAs (BRAF siRNA 1: J-003460-12-0005, BRAF siRNA 2: J-003460-13-0005) fol-
lowing the standard manufacturer’s protocol (Thermo Scientific Dharmacon, Lafayette, CO,
USA). Scrambled siRNA from the same manufacturer were utilized as negative controls. In
these experiments, 5000 MCF-7 cells were seeded into a 96-well format for knockdown and
subsequent MTS assays.
Western Blotting
Cells were starved of estrogen for 72 hours prior to indicated treatment conditions for 24
hours. Cells were then lysed in standard RIPA lysis buffer. Protein concentrations were deter-
mined with Qubit Protein Assay Kit (Invitrogen). 100 μg of protein was loaded into 10% poly-
acrylamide gels. After separation, the proteins were then applied to PVDF transfer membranes
(Thermo Fisher Scientific, Rockford, IL, USA). After transfer, the membranes were blocked in
TBST with 10% dissolved nonfat milk. After blocking, the membrane was probed with antibod-
ies directed against pERK1/2 (Cell Signaling, Danver, MA, USA), ERK1/2 (Cell Signaling),
BRAF (Santa Cruz), or GAPDH dissolved in 1% milk/TBST for 4 hrs to overnight. Membranes
were washed of unbound or non-specific antibody and reprobed with horseradish peroxidase
(HRP) specific secondary antibodies for 1 hr. Following a second wash, the film was exposed to
ECL reagent (Thermo Fisher Scientific), to allow for their detection by blue autoradiographic
film. All western blot experiments were carried out in biological triplicates. Fold change quanti-
fication in protein levels was analyzed using the densitometric analysis package in ImageJ soft-
ware (version 10.2) [26].
Illumina Bead Chip Arrays and Data Analysis
Total RNA fromMC7-7 cells was isolated with RNeasy columns (Qiagen). 250 ng of RNA was
converted to cRNA using the Illumina TotalPrep-96 RNA Amplification kit (Ambion, Carls-
bad, CA,USA). Next, cRNA from the amplification kit was hybridized to the Illumina Whole-
Genome Gene Expression Direct Hybridization Microarray (Illumina, San Diego, CA, USA).
The arrays were imaged in Illumina BeadArray Reader software, and were then further pro-
cessed in BeadStudio software (Illumina). Signal values from unambiguous probes were local
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background corrected and data across arrays were quantile normalized using the lumi package
from Bioconductor (https://www.bioconductor.org). Differentially expressed genes were deter-
mined by the limma package and p-values were false discovery rate corrected by the Benja-
mini-Hochberg procedure in R (http://r-project.org/). Genes with a correct p-value less than
0.05, as well as fold change values in excess of 1.1, were used to populate a list of responsive
genes for data mining. Gene ontology and pathway analysis of responsive genes were per-
formed using Pathway Studio (Ariadne Genomics, Rockville, MD). Fisher’s exact test was used
to determine statistically enriched pathways less than the standard p-value cutoff of 0.05. Gene
Set Enrichment Analysis (GSEA) was performed according to the instructions from the devel-
oper website (http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html) and the
responsive genes were compared to curated gene sets from the Molecular Signatures Database
(MSigDB). For false discovery correction, significant gene sets were defined as those with
familywise error rate (FWER)-corrected p-values of<0.05. The microarray data have been
uploaded to the Gene Expression Omnibus repository and will be available to the public follow-
ing publication (GSE66406).
Quantitative PCR
RNA from treated cells was extracted using the RNeasy Kit (Qiagen). Then, 0.5 μg of RNA was
reverse transcribed using SuperScript III Reverse Transcriptase System (Invitrogen). Quantita-
tive PCR was done on a 7500 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA,
USA) using Fast SYBR Green Master Mix (Applied Biosystems). Primer BLAST was used to
generate primers pairs for gene expression analysis (S1 Table). The ΔΔCt method was used to
calculate fold changes between treatment conditions by normalizing to 36B4, a housekeeping
gene (36B4 forward 50-GTGTTCGACAATGGCAGCAT-30; 36B4 reverse, 50-GACACCC
TCCAGGAAGCGA-30).
Survival Analysis
Clinical microarray gene expression data generated from a cohort of breast cancer patients in
Uppsala, Sweden were used to correlate responsive alcohol genes with disease parameters and
outcomes [27]. Dendrograms were generated with Eisen Cluster and Treeview software. Sur-
vival analyses were generated using the survival plot functions (log-rank test) of Mathematica
software. No consent or institutional review is required for this data as the analyses were based
on previously published and publically available data.
Results
Ethanol promotes estrogen and growth factor signaling mechanisms in
breast cancer cell lines
To optimize the study of the effects of alcohol on breast cancer cell proliferation, several
parameters were first established. MCF-7 breast cancer cells were primarily used in these stud-
ies because they are derived from the breast tumor subtype most commonly associated with
alcohol consumption (ER+/PR+). They are also the most frequently used ER+ cell line and the
most comprehensively studied. Cells were starved of estrogen (E2) in phenol-free medium sup-
plemented with 10% charcoal filtered FBS for 72 hours prior to the specified treatments. Drugs
and hormone compounds were dissolved in DMSO instead of ethanol to independently assess
the effects of alcohol on breast cancer cell biology. After starvation and treatment, we per-
formed trypan blue exclusion assays to evaluate whether alcohol is sufficient to drive ER+ breast
cancer cell line proliferation in the absence of estrogen, which is a major target in these types of
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breast cancer. These results showed that 21.7 mmol/L (0.1%) alcohol increased cell prolifera-
tion in MCF-7 cells only in the presence of estrogen (Fig 1A). Cells treated with ethanol in the
absence of E2 did not proliferate more than cells treated without ethanol (p = .77, FC = 0.97).
As a positive control, E2 significantly increased proliferation in ER+ MCF-7 cells over
untreated cells (p< 0.001). Alcohol further promoted a 21% increase in cell proliferation in E2
treated cells (p = 0.006), demonstrating that conditions used in these studies were sufficient to
evaluate breast cancer responses to alcohol. To establish the optimal working concentration of
alcohol for use in functional studies, we performed a titration of alcohol concentrations in
MCF-7 cells grown in cell medium containing estrogen, then subjected them to tetrazolium
salt reduction assays (MTS), which measure mitochondrial metabolic rate and act secondarily
as higher throughput reflections of cell number. In this assay, cells proliferated 24% more in
response to 43.4 mmol/L (0.2%) ethanol and elicited the most potent response (Fig 1B)
(p< 0.001 for 21.7, 43.4, and 65.1 mM ethanol treatments). Cells treated to 86.8 mM (0.4%)
ethanol were not statistically different from untreated cells, suggesting a suppressive effect on
cell proliferation at this concentration. Furthermore, 43.4 mM (0.2%) ethanol was slightly
more potent than 21.7 mM (0.1%) ethanol at increasing estrogen-dependent cell proliferation.
This concentration was used for the remaining cell proliferation experiments. A blood alcohol
Fig 1. Alcohol increases cell proliferation in an estrogen-dependent manner, promotes the activation
of ERK1/2, as well as known ER target genes. (A), Trypan blue exclusion assays demonstrate that
estrogen potentiates cell proliferation increases by alcohol. DMSO treated cells are not statistically different
from DMSO and alcohol cotreatment. (B), MTS assays measure statistically significant increases in
metabolic rate at 21.7, 43.4 and 65.1 mmol/L ethanol concentrations. Treatment with 86.8 mmol/L EtOH did
not result in an increase in cell proliferation. (C) Alcohol promotes the phosphorylation of ERK1/2, a key
effector of growth factor signaling and of G1-S progression, regardless of estrogen treatment. Quantification
comprises data of experiments in triplicate. (D) The effect of alcohol was tested on ER responsive genes
TFF1/pS2 and GREB1 in MCF-7 cells. Only GREB1 responds to alcohol treatment, suggesting a possible
overlap between cellular estrogen signaling and alcohol response.
doi:10.1371/journal.pone.0145061.g001
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content as low as 17.4 mM (~0.08%) begins to impair normal behaviors, and is considered a
binge drinking episode [28]. Furthermore, the alcohol concentrations used in the cell prolifera-
tion experiments are higher than the amount attained in average binge episodes, but are lower
than the achievable blood alcohol concentrations observed in alcohol patients [29].
Critical signals for estrogen-dependent cell proliferation are ERK1/2 phosphorylation,
which is mediated though increased ER target gene transcription in response to estrogen,
resulting in amplified HRG/HER2 signaling, and therefore increased growth [30]. To test
whether alcohol modulates these signaling mechanisms, we carried out western blot experi-
ments on combination estrogen and alcohol treated MCF-7 cells. These experiments showed
that alcohol increased ERK1/2 phosphorylation (Fig 1C). Furthermore, pERK was increased
1.49 fold (p = 0.01), whereas the pERK of E2 treated cells was increased 2.3 fold (p = 0.001).
Combination E2 and ethanol (0.2%) treatments increased pERK phosphorylation 2.8 fold rela-
tive to DMSO (p = 0.001). Alcohol promoted ERK phosphorylation in MCF-7 cells indepen-
dent of estrogen treatment, but is still required for increased cell proliferation, suggesting
estrogen-dependent and–independent mechanisms of alcohol activity in breast cancer cell
lines. Despite an effect by alcohol on ERK phosphorylation levels, these experimental results
demonstrated that alcohol is not sufficient to promote cell proliferation in the absence of
estrogen.
Our interests in the effects of alcohol on estrogen signaling are based partially on previously
published studies, which have shown that alcohol regulates estrogen receptor expression and
transcriptional activity [16, 31]. To confirm these results, MCF-7 cells were treated with alcohol
and/or E2 and subjected to gene expression analysis. TFF1/pS2 and GREB1 are two well-
known estrogen responsive genes (Fig 1D). GREB1 expression was amplified 15.09 fold in E2
and ethanol (0.1%) treated cells over DMSO. However, GREB1 was upregulated 11.46 fold in
cells treated with E2 alone. This difference was statistically significant (p = 0.05). Expression
levels of the TFF1/pS2 mRNA transcript, however, was not statistically different between E2
and E2/EtOH treated samples, suggesting that alcohol does not amplify the expression of estro-
gen responsive genes in a universal fashion.
Alcohol treatment regulates genes involved in key cellular processes
that are associated with patient survival and response to endocrine
therapy
To better characterize potential mechanisms of alcohol action in breast cancer cells, 0.1% etha-
nol-treated MCF-7 cells starved of estrogen were subjected to a genome-wide microarray anal-
ysis. Differentially expressed genes were defined by fold change cutoffs and false discovery
corrected p-values illustrated by a volcano plot of log10 transformed p-values plotted against
log2 transformed fold changes (Fig 2A). Significant fold changes (>+/-1.1) and false-discovery
corrected p-values (p<0.05) accepted for further analysis are highlighted in green. The 0.1375
log2 fold-change (equivalent to 10% or 1.1-fold change in either direction) was used to further
reduce the number of false-positives and increase the likelihood of validation by qPCR. It also
allowed for the capture of enough data points in order to determine overlap with estrogen-
responsive genes and for subsequent pathway and gene set enrichment analysis. Overall, 898
genes were upregulated, and 654 genes were down-regulated by ethanol (Fig 2B). A small por-
tion of these genes overlapped with known ER target genes [32]. Genes that were regulated by
alcohol treatment independent of a known ER binding site are termed “alcohol specific genes”
in this analysis. 77 up-regulated ethanol responsive genes overlapped with the 904 previously
identified ER target genes, whereas 37 down-regulated ethanol responsive genes overlapped
with known ER target genes (Fig 2B). A complete list of alcohol responsive genes is included in
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Fig 2. Gene networks regulated by alcohol treatment in MCF-7 cells are strongly correlated with
breast cancer disease parameters. (A) A representative volcano plot that depicts all probe fold changes
(log2) plotted against a their false-discovery corrected p-values (log10). Probes with a +/-1.1 fold change and
a p-value < 0.05 are depicted in green and are accepted alcohol-responsive genes used in downstream
analysis. (B) Representative Venn diagram demonstrating the number of up-regulated and down-regulated
Alcohol and Response to Tamoxifen in Breast Cancer
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S2 Table. A hypergeometric test revealed a statistically significant overlap between estrogen
responsive genes and up-regulated alcohol regulated genes (p-value = 5.4x10-8) and nearly sig-
nificant overlap between down-regulated alcohol responsive genes and estrogen responsive
genes (p-value = 0.0964), suggesting that alcohol does not generally affect ER target genes but
rather a specific subset in an apparently non-random manner. Gene ontology analysis showed
that alcohol responsive genes regulated a wide variety of molecular pathways. Up-regulated
alcohol-specific genes include those which governed cell cycle and apoptosis. Furthermore, the
down-regulated alcohol-specific genes are also involved in apoptosis, vesicle-mediated trans-
port, and response to oxidative stress (Table 1). The limited number of genes that overlapped
with estrogen signaling (ER target genes) were involved in cellular response to p53 activity, epi-
thelial cell maturation, and serotonin secretion (Table 2). In spite of the statistical association
between alcohol and estrogen responsive genes, pathway analysis of specific gene lists failed to
group into clear and cohesive consensus pathways, suggesting that the effects of alcohol on
genes, as well as the overlap of ethanol responsive genes with ER target genes. (C) Up-regulated and (D)
down-regulated alcohol responsive genes were analyzed for expression in a patient microarray (Upsalla
database). Yellow colors in the expression profiles indicate up-regulated genes, whereas blue colors
represent down-regulated genes. Patients were then clustered into two groups based on their gene
expression profiles in (C) up-regulated and (E) down-regulated gene subsets. Parameters were correlated for
DFS (disease-free survival), DMFS (mestastasis-free survival), and DSS (disease-specific survival). Survival
plots of subdivided patient groups show that both (D) up-regulated and (F) down-regulated alcohol
responsive genes are associated with clinical parameters and disease progression. (Patient dendrograms
correspond to survival plots based on color).
doi:10.1371/journal.pone.0145061.g002
Table 1. Gene ontology categories enriched in alcohol-specific responsive genes.
GO Category Study/Category p-value
Up-regulated Genes
cell cycle 54/604 5.02E-11
apoptosis 62/778 9.90E-11
chromatin modification 32/262 2.02E-09
protein ubiquitination 27/220 9.98E-09
protein transport 49/602 1.32E-10
protein phosphorylation 55/743 1.84E-07
cell proliferation 38/429 1.13E-08
interspecies interaction between organisms 32/325 2.84E-08
RNA splicing 31/323 2.44E-06
protein dephosphorylation 21/166 1.33E-05
response to DNA damage stimulus 30/309 3.18E-07
Down-regulated Genes
oxidation-reduction process 59/840 6.70E-11
transcription, DNA-dependent 113/2265 1.26E-08
apoptosis 51/778 3.67E-07
response to oxidative stress 19/150 4.25E-09
multicellular organismal development 66/1146 6.10E-07
vesicle-mediated transport 24/244 9.19E-08
tRNA processing 14/89 2.31E-06
viral reproduction 30/362 1.72E-07
carbohydrate metabolic process 30/369 8.14E-07
regulation of apoptosis 24/263 1.36E-06
doi:10.1371/journal.pone.0145061.t001
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estrogen-regulated pathways are limited and gene specific (in the absence of estrogen). How-
ever, these results provide early leads into potential ER-independent mechanisms that are
regulated by alcohol. To examine whether genes identified in the microarray experiments sig-
nificantly overlap with other gene sets and networks, we performed gene set enrichment analy-
sis on the alcohol responsive genes [33]. Up-regulated alcohol responsive genes are enriched
for those which were also up-regulated in studies of stressed bladder cancer cells (see Table 3).
Similarly, up-regulated responsive genes also showed enrichment for genes which were overex-
pressed in nasopharyngeal cancer as compared to normal tissues. These results suggest that
exposure to alcohol may affect a number of cancer-related pathways and mechanisms.
Table 2. Gene ontology categories enriched in alcohol-responsive ER target genes.
GO Category Study/
Cat.
p-value
Up-regulated Genes
positive regulation of DNA damage response, signal transduction by p53 class
mediator
2 / 70 2.03E-
04
regulation of bone resorption 3 / 297 2.30E-
04
epithelial cell maturation 1 / 2 2.45E-
04
cellular response to reactive oxygen species 1 / 2 6.87E-
04
sleep 1 / 2 7.47E-
04
osteoclast differentiation 1 / 2 7.47E-
04
activation of adenylate cyclase activity 1 / 2 7.47E-
04
cellular response to hypoxia 4 / 735 7.47E-
04
epithelial cell maturation involved in salivary gland development 1 / 3 7.47E-
04
serotonin secretion, neurotransmission 1 / 3 7.47E-
04
Down-regulated Genes
negative regulation of cell proliferation 4 / 399 2.02E-
04
regulation of axonogenesis 2 / 30 2.30E-
04
cellular response to starvation 2 / 31 2.45E-
04
response to organic cyclic compound 3 / 234 6.87E-
04
negative regulation of synaptic transmission, cholinergic 1 / 1 7.47E-
04
positive regulation of calcineurin-NFAT signaling pathway 1 / 1 7.47E-
04
negative regulation of hepatocyte growth factor biosynthetic process 1 / 1 7.47E-
04
endocardial cushion to mesenchymal transition involved in valve formation 1 / 1 7.47E-
04
mitral valve morphogenesis 1 / 1 7.47E-
04
doi:10.1371/journal.pone.0145061.t002
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To determine the potential clinical significance of alcohol responsive genes in breast cancer
patients, we examined their expression profiles of alcohol responsive genes in a microarray
dataset of breast cancers. This dataset contains expression data from a cohort of patients with
corresponding morbidity and mortality data. Only patients with ER+ breast cancers being
managed by endocrine therapy were included in this analysis, due to the clinical and pathologi-
cal parameters that are associated with alcohol consumption. Hierarchical clustering of these
patients was performed based on the expression profiles of alcohol up-regulated and down-reg-
ulated genes. Patients were then placed into one of two patient groups based on the hierarchical
clustering patterns (Fig 2C and 2E). Positive fold change values are depicted in yellow, whereas
negative fold changes are shown in blue. The two groups were subsequently analyzed for
Table 3. Top ten gene sets enriched in the alcohol-responsive genes.
Gene Sets FWER p-
val
PubMed
ID
Up-regulated Genes
Genes down-regulated in fibroblasts expressing mutant forms of ERCC3 after
UV irradiation
<0.001 15608684
Genes up-regulated in T1 cells (primary melanoma, sensitive to TRAIL)
compared to G1 cells (metastatic melanoma, resistant to TRAIL)
<0.001 16983347
Genes up-regulated in T24 (bladder cancer) cells in response to the
photodynamic therapy (PDT) stress
<0.001 17952126
Common down-regulated transcripts in fibroblasts expressing either XP/CS or
TDD mutant forms of ERCC3, after UVC irradiation
<0.001 15608684
Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1, a
latent gene of Epstein-Barr virus (EBV)
<0.001 16912175
Genes down-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation <0.001 12771951
Genes significantly de-regulated (p < 0.05) by MIR21 in A172 cells (glioma) 0.001 18591254
Genes up-regulated in nasopharyngeal carcinoma relative to the normal tissue 0.001 16912175
Genes down-regulated in HCT116 cells (colon cancer) by expression of
MIR192 or MIR215 at 24 h.
0.001 19074876
All significantly down-regulated genes in kidney glomeruli isolated from TCF21
knockout mice
0.002 16207825
Down-regulated Genes
Genes co-regulated in uterus during a time course response to progesterone:
SOM cluster 13
<0.001 12554760
Mitochondrial genes <0.001 12808457
Genes whose expression was significantly and positively correlated with the
number of perineuronal oligodendrocytes in the layer III of BA9 brain region
<0.001 18762803
Genes down-regulated in polysomal and total RNA samples from SW480 cells
(primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node
metastasis from the same individual)
<0.001 16531451
Mitochondrial genes; based on literature and sequence annotation resources
and converted to Affymetrix HG-U133A probe sets
<0.001 12808457
Genes up-regulated in lymphoblastoid cells from the European population
compared to those from the Asian population.
<0.001 17206142
Genes up-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of
EZH2 by RNAi
<0.001 20708159
Genes up-regulated by ESRRA only <0.001 18974123
Genes up-regulated in HeLa cells (cervical cancer) after simultaneous
knockdown of all three MBD (methyl-CpG binding domain) proteins MeCP2,
MBD1 and MBD2 by RNAi
0.002 18223687
Genes up-regulated in NHEK cells (normal epidermal keratinocytes) after UVB
irradiation
0.004 16434974
doi:10.1371/journal.pone.0145061.t003
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disease-free survival (recurrence; DFS), distant metastasis-free survival (metastasis; DMFS),
and disease specific survival outcomes (death; DSS). The up-regulated gene subset was associ-
ated with recurrence (p< 0.05), metastasis (p< 0.01), and death (p< 0.01) (Fig 2D). The
down-regulated subset clustered patients groups with very different recurrence, metastasis, and
death outcomes (p< 0.01, 0.025, and 0.001 respectively) (Fig 2F). Based on these survival anal-
yses, it appears that alcohol responsive genes may serve as prognostic markers for patient
response to endocrine therapy.
Alcohol blocks tamoxifen in ER+ breast cancer cell lines
Due to the potential association of alcohol with response to endocrine therapy, we tested the
hypothesis that alcohol may directly antagonize tamoxifen activity in breast cancer cells. In
these experiments, we utilized MTS assays to measure metabolic rate in two standard ER+ cell
lines (MCF-7 and T47D) and one ER- negative cell line (MDA-MB-231). As expected, the ER
+ cell lines proliferated in response to E2 (80% in MCF-7 cells and 32% in T47D cells when
compared to vehicle; p< 0.001 in both MCF-7 and T47D cells, Fig 3A and 3B). Furthermore,
alcohol increased proliferation an additional 38% in MCF-7 cells and 23% in T47D cells over
E2 alone (p 0.001 in both cell lines). As a control, tamoxifen treatment suppressed E2 induc-
tion of cell proliferation in both ER+ cell lines. To determine the association between alcohol
and response to tamoxifen, ethanol co-treatment with E2 and tamoxifen increased cell prolifer-
ation 24.8% and 13.8% in MCF-7 and T47D cells respectively over E2 and tamoxifen treated
cells (p< 0.01 in both cell lines). MDA-MB-231 cells did not respond to alcohol or ER ligands
(Fig 3C). These data provide a direct link between alcohol responsive genes and previously
published epidemiological data, in that expanded cell proliferation provided by estrogen and
other factors is often a risk factor for the development of breast cancer [34]. These data also
provide the mechanistic basis for the association between alcohol responsive genes and patient
response to endocrine therapy.
BRAF is a novel ethanol responsive gene that promotes breast cancer
cell proliferation
Previous analyses of ethanol responsive genes demonstrated a strong link between alcohol
responsive genes and clinical outcomes, but involved the clustering of patients based on a large
number of alcohol responsive genes (Fig 2). To ascertain the contributions of individual alco-
hol responsive genes to the phenotypes observed earlier, alcohol responsive genes were ana-
lyzed for their differential expression based on clinical outcomes in ER+ breast cancers treated
with endocrine therapy. Single genes with statistically significant differing expression levels
were identified in patients who experienced recurrence (DFS), metastasis (DMFS), or death
(DSS) (Table 4). Several, alcohol responsive genes were identified in the microarray analysis
and are involved in regulating cell proliferation (BRAF, SKP2, PPARG). These and other genes
involved in the metabolism of alcohol were validated by qPCR (Fig 4A). The top responsive
gene, BRAF, a protocol-oncogene and downstream effector of growth factor signaling and reg-
ulator of the mitogen activated protein kinase cascascadewas induced 2.00 fold over untreated
cells (p< 0.05) at the transcript level (Fig 4A). Ethanol promoted a 3.15 fold increase in BRAF
protein levels in MCF-7 cells (p = 0.008). Treatment with E2 increases BRAF levels 3.15 fold
(p = 0.001), whereas E2 and EtOH treatment increased BRAF levels 4.26 fold (p = .004). BRAF
levels for MCF-7 cells treated with E2 and alcohol were not always increased over E2 treatment
alone, but a distinct trend was present (p = 0.18) (Fig 4B). Taken together, these data show that
BRAF is a novel alcohol and estrogen responsive gene, which is overexpressed in breast cancer
patients with poorer DSS parameters.
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Due to its known roles in cell proliferation and oncogenesis and the activation of ERK phos-
phorylation in response to alcohol treatment (Fig 1), we examined the effect of BRAF on alco-
hol response in MCF-7 cells. First, BRAF siRNA knock-down suppressed BRAF transcript and
protein levels (Fig 4C). We then performed knock-downs of BRAF and determined their effects
on cell proliferation using MTS assays. Knock-down of BRAF attenuated basal proliferation
rates, as well as estrogen-dependent proliferation in MCF-7 cells. Furthermore, knock-down of
Fig 3. Alcohol enhances estrogen-dependent increases in cell proliferation and blocks tamoxifen
attenuation of cell proliferation in MCF-7 and T47D cells. (A), MTS assays demonstrate that alcohol is
able to increase measures of metabolic rate in estrogen-treated MCF7 cells. Alcohol also largely blocks a
dose of tamoxifen after 72 hours of treatment, suggesting a role for alcohol in breast cancer insensitivity to
SERMS. (B) Similar results were observed in another ER+ cell line, T47D. (C) MDA-MB-231 cells do not
respond to estrogen, tamoxifen, or ethanol.
doi:10.1371/journal.pone.0145061.g003
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BRAF was able to partially attenuate alcohol (0.2%) response, especially with construct 2 (Fig
4C). Furthermore, BRAF regulated basal, as well as estrogen-dependent proliferation in MCF-
7 cells. Lastly, BRAF expression is elevated in clinical samples from patients who responded
poorly to endocrine therapy as determined by DFS, DMFS, and DSS (Fig 5A). Kaplan-Meier
survival analysis of patients based on BRAF expression levels showed statistically significant
DMFS and DSS outcomes in ER+ breast cancer patients (p = .02 and 0.03, respectively), where
women with higher expression of the BRAF mRNA responded more poorly to endocrine ther-
apy (Fig 5B–5D). These results identified BRAF as a novel alcohol responsive gene that is
involved in breast cancer cell proliferation and whose expression is correlated with disease
outcomes.
Discussion
Approximately 60% of US women consume some alcohol annually (Women and Alcohol,
National Institute on Alcohol Abuse and Alcoholism, 2015). Among those who consume alco-
hol, 5.7 million women have alcohol use disorders. Alcohol consumption is associated with a
number of diseases, including increased risks in breast and other cancers. It is estimated that
up to 5% of all breast cancers in the US and Europe are attributable to alcohol consumption
[35]. Moreover, 50% of women with breast cancer consume some alcohol, and drinking is asso-
ciated with an increased risk of disease recurrence in women with early stage breast cancer
[25]. The aim of this study was to identify molecular pathways and mechanisms of alcohol
response in ER+ breast cancer cells. We first established that alcohol increases estrogen-
induced cell proliferation (Fig 1A), and these findings demonstrate that alcohol enhanced the
proliferative effects of estrogen. This contrasts with other studies, which were not able to
Table 4. Alcohol-responsive genes differentially expressed between outcome groups.
Gene DFS DMFS DSS
Up-regulated Genes
STIL 0.002 0.004 0.001
ASCL1 0.019 0.035 0.003
TULP4 0.244 0.008 0.005
RIF1 0.294 0.02 0.005
MIER3 0.002 0.007 0.007
BRAF 0.176 0.054 0.014
ID2 0.225 0.263 0.016
SKP2 0.505 0.081 0.022
TP53INP1 0.081 0.059 0.022
PHIP 0.594 0.65 0.049
Down-regulated Genes
WISP2 0.001 0.001 0.001
DIO2 0.013 0.007 0.002
H19 0.005 0.005 0.011
PPARG 0.132 0.048 0.014
VEGFB 0.012 0.023 0.020
RBPMS 0.121 0.141 0.025
DICER1 0.008 0.008 0.026
DHRS2 0.676 0.633 0.039
ITGB5 0.002 0.01 0.048
VGF 0.005 0.014 0.048
doi:10.1371/journal.pone.0145061.t004
Alcohol and Response to Tamoxifen in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0145061 December 14, 2015 13 / 21
identify the link between alcohol and estrogen in cell proliferation assays [31], likely due to the
lack of experiments performed on cells grown in estrogen-depleted medium containing growth
factors. Furthermore, we also identified the optimal concentration of alcohol for evaluating
proliferative responses in breast cancer cells while maintaining physiologically attainable levels
of alcohol. The most robust proliferative response was observed in MCF-7 cells treated to 43.4
mmol/L (0.2%) alcohol (Fig 1B). To address concerns of potential cytotoxic effects of alcohol,
previously published studies determined that cytotoxicity occurs at very high levels of alcohol
treatment (> 425 mmol/L), concentrations which were not evaluated in our study [21]. How-
ever, we found that the alcohol-dependent proliferative concentration window (between
21.7 mmol/L and ~65.1 mmol/L alcohol) was much lower than the cytotoxic dose of alcohol
(>425 mmol/L alcohol). These studies clarified the optimal parameters for studying ethanol
response, which was estrogen-dependent and fell well below cytotoxic thresholds observed in
other studies.
Estrogen signaling regulates and is highly integrated with growth factor signaling networks.
We determined that alcohol promoted a known key regulator of estrogen-induced cell prolifer-
ation, the phosphorylation of ERK1/2, independent of estrogen (Fig 1C). Phosphorylated
Fig 4. Alcohol regulates BRAF, an effector of growth factor signaling, and promotes estrogen-
dependent and–independent growth. (A), Microarray validation demonstrates subtle but highly
reproducible effects on gene expression of down-regulated and up-regulated genes. (B) BRAF is up-
regulated at the protein level by alcohol and estrogen treatment. (C) BRAF is targetable with siRNA
knockdown for functional studies. MTS assays demonstrate the anti-proliferative effect of BRAF knockdown
on MCF-7 cells, suggesting that BRAF promotes basal cell proliferation in the absence of estradiol, increases
estrogen-dependent growth, and potentiates some of the cell’s response to ethanol.
doi:10.1371/journal.pone.0145061.g004
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Fig 5. High BRAF expression levels correlated ER+ endocrine treated patients with poor prognosis
and response to therapy. (A) BRAF is expressed at higher levels in patients who experience poor disease
outcomes as compared to those who did not experience an adverse event. (B) BRAF expression levels
separate patients into different DFS groups with nearly significant p-value (p = 0.074). Statistically different
(C) DMFS and (D) DSS groups are observed in ER+ endocrine treated patients based on high expression
levels of BRAF.
doi:10.1371/journal.pone.0145061.g005
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ERK1/2 are required for G1-S transition, and are thought to control early events in G1 by up-
regulating pyrimidine synthesis, regulating protein translation, or activating transcription fac-
tors involved in subsequent cell cycle processes [36–39]. It appears from these results that alco-
hol promoted both estrogen- and alcohol-specific responses, as increased pERK1/2 did not
result in increased proliferation in the absence of estrogen. Potential mechanisms of ERK1/2
regulation have been proposed in other studies. Increased ERK signaling could be due to the
inactivation of phosphatases by reactive oxygen species (ROS) generated from alcohol detoxifi-
cation, allowing for the accumulation of activating phosphorylation marks on growth factor
receptors [40–42]. An alternative mechanism of the effects of alcohol on growth factor signal-
ing pathways is that alcohol generated ROS lead to the inappropriate activation of matrix
metalloproteinases, which are known to stimulate the activity of growth factor signaling ligands
[20, 42]. A well-known transcriptional effector of ERK activity is activated ELK1 [43]. This fac-
tor is a potent inducer of c-fos, which is up-regulated in our microarray dataset (FC = 1.27).
This is suggestive of increased ELK1 activity downstream of activated ERK. These results form
an important link between the two critical pathways in breast cancer, growth factor signaling
and estrogen signaling, which are both regulated by alcohol.
Alcohol has been shown to up-regulate the expression of an estrogen responsive luciferase
reporter gene [16], an effect which was shown to require estrogen. However, the effect of alco-
hol on the expression of ER target genes on endogenous promoters has not been extensively
explored. We showed that alcohol further increased GREB1 expression after estrogen treat-
ment, suggesting that alcohol promotes hyper-activation of estrogen signaling in breast cancer
cells (Fig 1D). TFF1/pS2, however, did not respond to alcohol treatment, possibly due to ER
saturation of that promoter, negative feedback loops on transcription of the gene target, treat-
ment time conditions, or was otherwise insensitive to the effected mechanisms of alcohol treat-
ment. These findings contrasted with another study that described a TFF1/pS2 response to
alcohol treatment, albeit the regulation was relatively subtle. We were unable to reproduce this
effect in MCF-7 cells, possibly due to differences in experimental design [31].
From genome-wide microarray studies of alcohol treated cells, we first observed that a sig-
nificant proportion of the genome responded to alcohol treatment (Fig 2A). Overall, the mag-
nitude of differential expression of alcohol responsive genes was modest. This is not surprising
given that alcohol is not known to be a ligand for key cell signaling pathways which can
robustly activate downstream transcriptional regulatory networks. It is most likely that subtle
changes across multiple pathways and gene networks are involved in the effects of alcohol on
breast cancer cell biology. An example of subtle changes in gene sets having a biological impact
is the study by Mootha et al., to identify genes differentially expressed in diabetic muscle sam-
ples as compared to normal controls [44]. Their inability to detect any significant changes
prompted the development of GSEA [33]. The subtle changes in gene sets identified in the
study were subsequently determined experimentally to be functionally important in follow-up
studies [45]. Due to the depletion of estrogen in the cell culture medium, we were able to assess
whether alcohol could transactivate ER target genes independent of estrogen. A hypergeomet-
ric test revealed a statistically significant overlap between up-regulated alcohol genes and
known estrogen responsive genes, which suggests that a subset of estrogen responsive genes
was impacted by alcohol (independently of estrogen). These data also suggest, especially in
light of the estrogen-independent effect of alcohol on ERK1/2 phosphorylation, that alcohol-
specific genes may potentially enhance estrogen dependent cell proliferation. To test this
hypothesis, alcohol responsive genes were further analyzed for statistically enriched gene ontol-
ogy categories. Cell cycle genes (CCND2, RAD17, EP300) were up-regulated in MCF-7 cells
treated with alcohol (Table 1). Genes involved in protein phosphorylation (ROCK1/2, JAK2,
SMAD5) and dephosphorylation (DUSP1/12, BCL2, PTP) were also regulated by alcohol
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treatment. As previously mentioned, cell cycle machinery is heavily dependent upon posttrans-
lational modifications for correct regulation of growth factor signaling cascades, which could
explain the enrichment of gene ontology categories involved in general protein phosphoryla-
tion. Genes involved in oxidative-reduction responses (P53, SOD1, HMOX1) and apoptotic
genes (CASP2, BID, VIM) were enriched in the down-regulated alcohol specific gene subset.
These data indicate that alcohol regulates a number of pathways that have known critical roles
in breast carcinogenesis.
To ascertain the clinical significance of the alcohol-responsive genes, their expression pro-
files and association with disease outcomes were analyzed in a microarray dataset from tumors
obtained from a cohort of patients who received endocrine therapy. Expression profiles of both
up-regulated (Fig 2C) and down-regulated (Fig 2D) genes were strongly associated with recur-
rent (DFS), metastasis (DMFS), and death (DSS). It is not clear from these data what roles
these genes, as a whole, may play in breast carcinogenesis, disease progression, and response to
SERMs, but their association with response to endocrine therapy suggests that alcohol treat-
ment affects the expression of a large number of genes which, at the very least, are prognostic
markers of therapeutic response and may function in key molecular pathways and mecha-
nisms. At the molecular level, normal ER activity in breast cancer cells is antagonized by
SERMs, which prevents estrogen-dependent cell proliferation [46, 47]. Due to the differences
in patient outcomes based on the gene expression profiles in patients of alcohol responsive
genes, we suspected that alcohol might promote breast cancer cell proliferation even in the
presence of tamoxifen. In agreement with this hypothesis, we determined that alcohol treat-
ment attenuated tamoxifen suppression of cell proliferation in MCF-7 (Fig 3A) and T47D cell
lines (Fig 3B). MDA-MB-231 cells did not respond to any of the treatment conditions, suggest-
ing that ER and ER- associated factors mediate the effects of tamoxifen and alcohol. Several
mechanisms of tamoxifen insensitivity have been previously identified. BRCA1 levels have
been shown to be down-regulated by alcohol treatment [16]. Down-regulated BRCA1 levels
lead to increased cell proliferation in the presence of tamoxifen by altering its interactions with
transcriptional coregulators and alter the nature of ligand-bound ER and its downstream tran-
scriptional responses [47]. BRCA1 was not down-regulated in our microarray analysis, which
suggests that alcohol mediates its effects on BRCA1 through non-transcriptional mechanisms.
Alternatively, amplified growth factor signaling can lead to increased cell proliferation in the
presence of tamoxifen. In this study, we showed that growth factor signaling (pERK1/2) is acti-
vated in response to alcohol treatment, which has been shown in other studies to be up-regu-
lated in tamoxifen resistant tumors (Fig 1C) [46]. These data together provide experimental
evidence that alcohol can directly block the effects of tamoxifen and may lead to poor clinical
outcomes and responses to therapy.
To further determine the mechanisms of action of alcohol in breast cancer biology, individ-
ual responsive genes were analyzed for differential expression based on clinical outcomes and
response to endocrine therapy in ER+ breast cancer patients (Table 2). WISP2, for instance, is
consistently down-regulated in ethanol treated cells, and has been shown to prevent migration
in MCF-7 cells by up-regulating E-cadherin expression and down-regulating MMP9 activity
[17]. The repressed gene dehydrogenase/reductase enzyme 2 (DHRS2) is expressed in MCF-7
cells, and is more highly expressed in luminal cells compared to basal cells, suggesting a link
between higher expression of this protein and a less aggressive luminal phenotype [48].H19, or
maternally expressed H19, is a long non-coding RNA that has been shown to attenuate let-7
activity, a microRNA that regulates cell proliferation and apoptosis [49]. Deletions of the H19
mRNA have also been shown to lead to overgrowth in transgenic mouse models, possibly
due to disrupted IGF-2 regulation [50]. Short-chain dehydrogenase/reductase 3 (DHRS3) has
been identified as a p53 responsive gene, and functions to reduce all-trans-retinal to replenish
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bleached retinoids in the visual cycle [51]. DHRS3 is potently induced by retinoic acid, an anti-
proliferative vitamin-A derivative so alcohol may interact with vitamin-A associated pathways
in breast cancer cell lines [52]. Transforming growth factor β-induced (TGFBI) is a secreted
protein and is also responsive to retinoic acid treatment in MCF-7 cells and has been shown to
prevent both anchorage-independent growth in MCF-7 cells and the development of meta-
static lesions in mouse xenograft models [42] [53]. The SCL/TAL1 (STIL) interrupting locus
gene is required for cell-cycle progression, as well as for centriole biogenesis and function [54,
55]. STIL attenuation prevents tumor growth in mouse colon cancer xenograft models [56].
The functional studies in this paper focused on BRAF, an effector of the growth factor signaling
and upstream regulator of the mitogen-activated protein kinase/ERK cascade and a therapeutic
target in other cancers such as melanoma [57, 58]. The observed effects of up-regulated ERK1/
2 phosphorylation in response to alcohol treatment suggest a role for BRAF in alcohol respon-
sive signaling pathways and effects (Fig 1C). BRAF is a novel alcohol- and estrogen-responsive
gene, and its transcript levels were negatively correlated with patient survival and response to
endocrine therapy (Fig 5). These findings suggest that alcohol inappropriately promotes sus-
tained expression of BRAF, even in the absence of estrogen, in women who consume alcohol
and may thereby mimic or enhance the effects of estrogen in increasing breast cancer risks. We
determined that BRAF inhibitor sorafenib led to dramatic increases in cell proliferation (data
not shown). Interestingly, this observation is in agreement with other studies that measured
increased cell proliferation in the presence of BRAF inhibitors in cell lines lacking constitutive
BRAF activity [59]. It is based on these observations that MCF-7 cells likely harbor wild-type
BRAF. BRAF inhibitors do not appear to alter overall BRAF levels, which could explain the dif-
ference in outcomes between the use of molecular inhibitors and, in our case, siRNA knock-
downs that blocked BRAF expression. A possible option for disrupting the effects of alcohol
and BRAF, other than a BRAF inhibitor, is to block ERK activity using existing small molecule
inhibitors. These findings not only shed light on mechanistic actions of alcohol in breast cancer
but also provide insights into the cross-talk between alcohol and known and novel oncogenic
pathways in breast cancer in general.
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